Up coming potential catalysts Q2 -- Bria-OTS - authorization by FDA ( 1st patient dosed)
Q3 Bria-OTS pre-reg study data
Q4 registration study - Bria-IMT + checkpoint inhibitor
these milestones set the stage for a potentially prosperous 2022. The resent up tick in volume suggest we are on point for Q2 .. we have 31% insider ownership so any positive news should give this a nice push.. I should add they have had discussions with several Big Pharma companies. Maybe a partnership is in the pipeline. Great luck all let's hope for another green one tomorrow ..